Institute of Hematology & Blood Diseases Hospital, China
Phase
Not applicable
Started
2024-02-29
Last updated
2024-08-13
Condition(s) studied
Transplant-Related Disorder
Investigational drug(s) / intervention(s)
Health monitoring and regular return follow-up reminders
Health monitoring and regular return follow-up reminders: Health monitoring \& reminders for blood tests and follow-up visits until 1 year post-transplant
Study summary
To assess the effectiveness of interventions including health monitoring and regular return follow-up reminders for patients with a high Composite Immune Risk Score.
Eligibility
Sex
ALL
Min age
16 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* 1\) Patients must be ≥ 16 years of age;
* 2\) Patients receiving haploidentical allo-HSCT;
* 3\) Patients have to sign an informed consent form before the start of the research procedure.
Exclusion Criteria:
* 1\) Tandem transplantation or multiple transplantations;
* 2\) Mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements;
* 3\) Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.
Primary outcome measure(s)
Survival — 1.5 years after transplantation Overall survival during 1.5 years after transplantation
Trial sites (1)
Facility
City
Region
Status
Institute of Hematology & Blood Diseases Hospital
Tianjin
Tianjin Municipality
Recruiting
More Institute of Hematology & Blood Diseases Hospital, China trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.